Bioshares

Delivering independent investment research to investors on Australian biotech, pharma and healthcare companies.

The Bioshares Advantage

Bioshares is an investment report tailored to needs of biotech and healthcare investors. It is delivered electronically each week. That means **you are kept up to date**.

Bioshares is not wishy-washy. We are independent. We tell investors whether to buy, sell or hold a stock. You're not left confused by new-fangled broker gobbledegook. You get our opinion, delivered fairly and squarely.

You get the **best written**, **most readable**, **most consistent** biotech research produced in Australia.

Can you get more coverage of biotech and healthcare stocks than in Bioshares? We don't think so.

Bioshares **covers around 70 of the 125 companies** in the sector.

Bioshares doesn't paint itself into a corner when it comes to biotech investing. What happens? We educate. We inform. You learn. You stay ahead. You make money. We aim to get you in and out of stocks before the crowd comes along.

	ates (inc. GST) 1700 ronic distribution): \$470
For multiple email distributions we the same business cost centre, our pricing structure is as follows:	\$1010 4-5 email addresses
To subscribe, post/fax this subscription form to:	Bioshares PO Box 193 Richmond VIC 3121 Fax: 61 3 9329 3350
I enclose a cheque for \$470 made payable to Blad	ke Industry & Market Analysis Pty Ltd, or
Please charge my credit card \$470 Maste	erCard
Card Number	
Signature	Expiry date
Subscriber details	
Name	
Organisation	
Ph ()	
Email (must be completed)	
Bioshares is published by Blake Industry and Market A	2 Email: info@bioshares.com.au nalysis Pty Ltd ABN 47 085 334 292 Ph: 03 9326 5382 e No 258032